Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Colorectal Neoplasms 34Carcinoma, Non-Small-Cell Lung 26Breast Neoplasms 25Lung Neoplasms 24Colonic Neoplasms 18Head and Neck Neoplasms 16Rectal Neoplasms 14Sarcoma 10Prostatic Neoplasms 10Neoplasm Metastasis 9Pancreatic Neoplasms 8Neoplasms 7Mouth Neoplasms 7Melanoma 7Esophageal Neoplasms 7Ovarian Neoplasms 6Glioblastoma 6Adenomatous Polyposis Coli 6Precancerous Conditions 5Neuroblastoma 5Liver Neoplasms 5Central Nervous System Neoplasms 5Carcinoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Oropharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4Epoetin Alfa 3Darbepoetin alfa 3Curcumin 3liposomal amphotericin B 2fludarabine phosphate 2Morphine 2Methylprednisolone 2Interferon-alpha 2Filgrastim 2Cyclosporine 2Caspofungin 2Carboplatin 2Bortezomib 2Antilymphocyte Serum 2tanespimycin 1siltuximab 1sargramostim 1pyroxamide 1piperine 1isatuximab 1ibrutinib 1ferrous sulfate 1ferric gluconate 1alethine 1aldesleukin 1Whole-Body Irradiation 1Topotecan 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Monoclonal Gammopathy of Undetermined Significance × Celecoxib × Clear all
NCT00099047 2016-12-30

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 7 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡